According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Several other research analysts have also recently weighed in on the company. HC Wainwright boosted their target price on Capricor Therapeutics from $14.00 to $18.00 and gave the stock a buy rating in a report on Monday, January 31st. StockNews.com initiated coverage on Capricor Therapeutics in a report on Thursday, March 31st. They set a sell rating on the stock.
Capricor Therapeutics (NASDAQ:CAPR – Get Rating) last posted its quarterly earnings data on Thursday, March 10th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.07). During the same period in the prior year, the business posted ($0.21) earnings per share. As a group, analysts expect that Capricor Therapeutics will post -1.1 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in CAPR. Barclays PLC raised its position in Capricor Therapeutics by 246.1% in the third quarter. Barclays PLC now owns 6,330 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 4,501 shares during the period. Two Sigma Securities LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $46,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Capricor Therapeutics during the first quarter worth $51,000. Goldman Sachs Group Inc. purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $89,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $115,000. 9.49% of the stock is currently owned by institutional investors.
About Capricor Therapeutics (Get Rating)
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
- Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.